Business
Illumina launches TruPath Genome, setting a new standard in genomic insight
Illumina, Inc. (NASDAQ: ILMN) today announced the launch of TruPath™ Genome, setting a new standard for high-quality, comprehensive whole genome insights for genetic disease. TruPath Genome has been found to deliver unparalleled accuracy and resolution—even across so-called "dark regions" of the genome—providing researchers with a more complete picture of genomic alterations implicated in genetic disease.
About this update from Illumina, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"TruPath™ Genome offers more complete genome, with the simplest sample to sequencer workflow","length":91,"tagName":"p"}]},{"val":[{"type":"text","content":"Data presented at AGBT demonstrates TruPath Genome's accuracy in detecting rare genetic disease","length":99,"tagName":"p"}]},{"val":[{"type":"text","content":"Broad Clinical Labs is among first to adopt product, which was previously known as "constellation mapped read technology"","length":131,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":321,"olType":false},{"type":"text","content":"SAN DIEGO, Feb. 24, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the launch of TruPath™ Genome, setting a new standard for high-quality, comprehensive whole genome insights for genetic disease. TruPath Genome has been found to deliver unparalleled accuracy and resolution—even across so-called "dark regions" of the genome—providing researchers with a more complete picture of genomic alterations implicated in genetic disease.","length":464,"tagName":"p"},{"type":"text","content":"With an incredibly simple workflow, TruPath Genome eliminates traditional library prep. In about 10 minutes of hands-on time, TruPath Genome generates 16 whole genomes per day, nearly double the throughput of competing long-read methods, and with fewer errors.","length":260,"tagName":"p"},{"type":"text","content":"TruPath Genome leverages novel on-flow cell library preparation with patterned flow cell technology and advanced informatics to seamlessly add long-distance insights for comprehensive variant detection. DRAGEN™ algorithms tuned to incorporate proximity information from TruPath flow cells improve read alignment and variant calling, extending Illumina high-quality reads to difficult-to-map regions, variant phasing, structural variants, short tandem repeats (STR), and clinically relevant paralogous genes. TruPath Genome fully phases up to 98% of genes.","length":555,"tagName":"p"},{"type":"text","content":""With TruPath Genome, we are pushing the boundaries of genomics and setting a new standard for genetic and rare disease research," said Steve Barnard, PhD, chief technology officer of Illumina. "In rare disease, you're often looking for a variant needle in a genomic haystack—and comprehensiveness,...